Targeting cancer stem cells and signalling pathways through phytochemicals: A promising approach against colorectal cancer. 2023

Wenhao Liao, and Lanlan Zhang, and Xian Chen, and Juyi Xiang, and Qiao Zheng, and Nianzhi Chen, and Maoyuan Zhao, and Gang Zhang, and Xiaolin Xiao, and Gang Zhou, and Jinhao Zeng, and Jianyuan Tang
Department of Oncology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China.

BACKGROUND Cancer stem cells (CSCs) are strongly associated with high tumourigenicity, chemotherapy or radiotherapy resistance, and metastasis and recurrence, particularly in colorectal cancer (CRC). Therefore, targeting CSCs may be a promising approach. Recently, discovery and research on phytochemicals that effectively target colorectal CSCs have been gaining popularity because of their broad safety profile and multi-target and multi-pathway modes of action. OBJECTIVE This review aimed to elucidate and summarise the effects and mechanisms of phytochemicals with potential anti-CSC agents that could contribute to the better management of CRC. METHODS We reviewed PubMed, EMBASE, Web of Science, Ovid, ScienceDirect and China National Knowledge Infrastructure databases from the original publication date to March 2022 to review the mechanisms by which phytochemicals inhibit CRC progression by targeting CSCs and their key signalling pathways. Phytochemicals were classified and summarised based on the mechanisms of action. RESULTS We observed that phytochemicals could affect the biological properties of colorectal CSCs. Phytochemicals significantly inhibit self-renewal, migration, invasion, colony formation, and chemoresistance and induce apoptosis and differentiation of CSCs by regulating the Wnt/β-catenin pathway (e.g., diallyl trisulfide and genistein), the phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin pathway (e.g., caffeic acid and piperlongumine), the neurogenic locus notch homolog protein pathway (e.g., honokiol, quercetin, and α-mangostin), the Janus kinase-signal transducer and activator of transcription pathway (e.g., curcumin, morin, and ursolic acid), and other key signalling pathways. It is worth noting that several phytochemicals, such as resveratrol, silibinin, evodiamine, and thymoquinone, highlight multi-target and multi-pathway effects in restraining the malignant biological behaviour of CSCs. CONCLUSIONS This review demonstrates the potential of targeted therapies for colorectal CSCs using phytochemicals. Phytochemicals could serve as novel therapeutic agents for CRC and aid in drug development.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014411 Neoplastic Stem Cells Highly proliferative, self-renewing, and colony-forming stem cells which give rise to NEOPLASMS. Cancer Stem Cells,Colony-Forming Units, Neoplastic,Stem Cells, Neoplastic,Tumor Stem Cells,Neoplastic Colony-Forming Units,Tumor Initiating Cells,Cancer Stem Cell,Cell, Cancer Stem,Cell, Neoplastic Stem,Cell, Tumor Initiating,Cell, Tumor Stem,Cells, Cancer Stem,Cells, Neoplastic Stem,Cells, Tumor Initiating,Cells, Tumor Stem,Colony Forming Units, Neoplastic,Colony-Forming Unit, Neoplastic,Initiating Cell, Tumor,Initiating Cells, Tumor,Neoplastic Colony Forming Units,Neoplastic Colony-Forming Unit,Neoplastic Stem Cell,Stem Cell, Cancer,Stem Cell, Neoplastic,Stem Cell, Tumor,Stem Cells, Cancer,Stem Cells, Tumor,Tumor Initiating Cell,Tumor Stem Cell,Unit, Neoplastic Colony-Forming,Units, Neoplastic Colony-Forming
D015179 Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI. Colorectal Cancer,Colorectal Carcinoma,Colorectal Tumors,Neoplasms, Colorectal,Cancer, Colorectal,Cancers, Colorectal,Carcinoma, Colorectal,Carcinomas, Colorectal,Colorectal Cancers,Colorectal Carcinomas,Colorectal Neoplasm,Colorectal Tumor,Neoplasm, Colorectal,Tumor, Colorectal,Tumors, Colorectal
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D051880 Receptors, Notch A family of conserved cell surface receptors that contain EPIDERMAL GROWTH FACTOR repeats in their extracellular domain and ANKYRIN REPEATS in their cytoplasmic domains. The cytoplasmic domains are released upon ligand binding and translocate to the CELL NUCLEUS, where they act as transcription factors. Notch Protein,Notch Receptor,Notch Receptors,Notch Proteins,Protein, Notch,Receptor, Notch
D060449 Wnt Signaling Pathway A complex signaling pathway whose name is derived from the DROSOPHILA Wg gene, and the vertebrate INT gene. The signaling pathway is initiated by the binding of WNT PROTEINS to cell surface WNT RECEPTORS which interact with the AXIN SIGNALING COMPLEX and an array of second messengers that influence the actions of BETA CATENIN. Wnt Signaling,Wnt Pathway,Wnt Pathway, Canonical,Wnt beta-Catenin Signaling Pathway,Canonical Wnt Pathway,Canonical Wnt Pathways,Pathway, Canonical Wnt,Pathway, Wnt,Pathway, Wnt Signaling,Signaling Pathway, Wnt,Signaling, Wnt,Wnt Signaling Pathways,Wnt Signalings,Wnt beta Catenin Signaling Pathway
D064209 Phytochemicals A broad range of biologically active compounds which occur naturally in plants having important medicinal and nutritional properties. Dietary Phytochemical,Plant Bioactive Compound,Plant Biologically Active Compound,Plant-Derived Chemical,Plant-Derived Compound,Bioactive Coumpounds, Plant,Biologically Active Coumpounds, Plant,Dietary Phytochemicals,Phytochemical,Phytonutrient,Phytonutrients,Plant Bioactive Compounds,Plant Biologically Active Compounds,Plant-Derived Chemicals,Plant-Derived Compounds,Bioactive Compound, Plant,Bioactive Compounds, Plant,Chemical, Plant-Derived,Chemicals, Plant-Derived,Compound, Plant Bioactive,Compound, Plant-Derived,Compounds, Plant Bioactive,Compounds, Plant-Derived,Coumpounds, Plant Bioactive,Phytochemical, Dietary,Phytochemicals, Dietary,Plant Bioactive Coumpounds,Plant Derived Chemical,Plant Derived Chemicals,Plant Derived Compound,Plant Derived Compounds

Related Publications

Wenhao Liao, and Lanlan Zhang, and Xian Chen, and Juyi Xiang, and Qiao Zheng, and Nianzhi Chen, and Maoyuan Zhao, and Gang Zhang, and Xiaolin Xiao, and Gang Zhou, and Jinhao Zeng, and Jianyuan Tang
October 2016, Seminars in cancer biology,
Wenhao Liao, and Lanlan Zhang, and Xian Chen, and Juyi Xiang, and Qiao Zheng, and Nianzhi Chen, and Maoyuan Zhao, and Gang Zhang, and Xiaolin Xiao, and Gang Zhou, and Jinhao Zeng, and Jianyuan Tang
January 2017, International journal of cancer,
Wenhao Liao, and Lanlan Zhang, and Xian Chen, and Juyi Xiang, and Qiao Zheng, and Nianzhi Chen, and Maoyuan Zhao, and Gang Zhang, and Xiaolin Xiao, and Gang Zhou, and Jinhao Zeng, and Jianyuan Tang
April 2013, Drug delivery and translational research,
Wenhao Liao, and Lanlan Zhang, and Xian Chen, and Juyi Xiang, and Qiao Zheng, and Nianzhi Chen, and Maoyuan Zhao, and Gang Zhang, and Xiaolin Xiao, and Gang Zhou, and Jinhao Zeng, and Jianyuan Tang
June 2020, International journal of molecular sciences,
Wenhao Liao, and Lanlan Zhang, and Xian Chen, and Juyi Xiang, and Qiao Zheng, and Nianzhi Chen, and Maoyuan Zhao, and Gang Zhang, and Xiaolin Xiao, and Gang Zhou, and Jinhao Zeng, and Jianyuan Tang
November 2017, Cancer immunology, immunotherapy : CII,
Wenhao Liao, and Lanlan Zhang, and Xian Chen, and Juyi Xiang, and Qiao Zheng, and Nianzhi Chen, and Maoyuan Zhao, and Gang Zhang, and Xiaolin Xiao, and Gang Zhou, and Jinhao Zeng, and Jianyuan Tang
March 2019, Molecules (Basel, Switzerland),
Wenhao Liao, and Lanlan Zhang, and Xian Chen, and Juyi Xiang, and Qiao Zheng, and Nianzhi Chen, and Maoyuan Zhao, and Gang Zhang, and Xiaolin Xiao, and Gang Zhou, and Jinhao Zeng, and Jianyuan Tang
August 2008, Molecular interventions,
Wenhao Liao, and Lanlan Zhang, and Xian Chen, and Juyi Xiang, and Qiao Zheng, and Nianzhi Chen, and Maoyuan Zhao, and Gang Zhang, and Xiaolin Xiao, and Gang Zhou, and Jinhao Zeng, and Jianyuan Tang
January 2021, Current medicinal chemistry,
Wenhao Liao, and Lanlan Zhang, and Xian Chen, and Juyi Xiang, and Qiao Zheng, and Nianzhi Chen, and Maoyuan Zhao, and Gang Zhang, and Xiaolin Xiao, and Gang Zhou, and Jinhao Zeng, and Jianyuan Tang
January 2020, Frontiers in oncology,
Wenhao Liao, and Lanlan Zhang, and Xian Chen, and Juyi Xiang, and Qiao Zheng, and Nianzhi Chen, and Maoyuan Zhao, and Gang Zhang, and Xiaolin Xiao, and Gang Zhou, and Jinhao Zeng, and Jianyuan Tang
January 2024, Current medicinal chemistry,
Copied contents to your clipboard!